Trial Profile
A phaseI/II study of TS-1 and Docetaxel with Metastatic Breast Cancer patients resisting for Docetaxel.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TABRET
- 11 Dec 2011 Planned end date (Dec 2011) added as reported by University Hospital Medical Information Network - Japan.
- 11 Dec 2011 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 01 Aug 2009 Actual initiation date (Aug 2009) added as reported by University Hospital Medical Information Network - Japan.